Skip to search formSkip to main contentSkip to account menu

Gamunex

National Institutes of Health

Related topics

Related topics

5 relations
10 ML Immunoglobulin G, Human 100 MG/ML Injection [Gamunex]50 ML Immunoglobulin G, Human 100 MG/ML Injection [Gamunex]

Broader (3)

Immunoglobulin GImmunoglobulin G, HumanImmunoglobulins, Intravenous

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Gamunex® in Guillain-Barré Syndrome: A Postmarketing, Retrospective, Observational Study
Abstract Background: The objective of this retrospective study was to evaluate the effectiveness and safety of Gamunex® (immune… 
2014
2014
Specific binding of intravenous immunoglobulin products to tau peptide fragments.
2011
2011
Biocompatibility of pooled human immunoglobulin (Gamunex 10%™) with ocular infusion solutions (BSS™ and BSS Plus™): an in vitro evaluation of a potential antitoxin treatment for infectious…
PURPOSE Gamunex 10% (Talecris Biotherapeutics, Research Triangle Park, NC), a commercially available preparation of pooled human… 
2010
2010
Relevance of quantitative measurements of anti-Abeta antibodies in therapeutic intravenous immunoglobulin using synthetic peptides.
2003
2003
Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IGIV-C, 10% (Gamunex, 10%).
BACKGROUND AND OBJECTIVES A new intravenous immunoglobulin (IGIV) process has been developed that integrates efficient… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)